Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04247126 · ClinicalTrials.gov registry record · Phase 1
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
A Phase 1 study of Breast Cancer and Pancreatic Cancer, sponsored by Syros Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
- 16
- Study locations
NCT04247126: Completed Phase 1 study of Breast Cancer and Pancreatic Cancer, sponsored by Syros Pharmaceuticals.
NCT04247126 is a Phase 1 study of Breast Cancer and Pancreatic Cancer that has completed, run by Syros Pharmaceuticals. The registered enrollment target is 105 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 16 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04247126, a Phase 1 study of Breast Cancer and Pancreatic Cancer, has completed, sponsored by Syros Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
- 16
- Study locations
Study Summary
The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first administer SY-5609 in combination with gemcitabine and then SY-5609 in combination with gemcitabine and nab-paclitaxel in participants with pancreatic ductal adenocarcinoma (PDAC) .
Conditions Studied
Interventions
- DRUG Fulvestrant
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG SY-5609
Study Locations (16)
California
- Cedars-Sinai Medical Center - Los Angeles
- University of California Los Angeles - Los Angeles
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Michigan
- University of Michigan - Ann Arbor
- START Midwest, LLC - Grand Rapids
Arizona
- Banner MD Anderson Cancer Center - Gilbert
Florida
- Orlando Health Cancer Institute - Orlando
Georgia
- Emory University - Atlanta
Iowa
- The University of Iowa - Iowa City
Maryland
- Johns Hopkins University - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2020-01-23 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 1 |
What the finished NCT04247126 record still lists
NCT04247126 is an interventional study that assigns participants to a tested intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 4 interventions - of which Fulvestrant is the first listed.
NCT04247126 lists 16 locations in 13 states (California, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT04247126 about?
NCT04247126 is a clinical study titled "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors". The study consists of 2 parts. Part 1 is dose escalation and will first administer SY-5609 alone to participants with select advanced solid tumors and then in combination with fulvestrant to participants with HR positive, HER2-negative breast cancer. Part 2 is a dose expansion and will first adminis...
What is the current status of trial NCT04247126?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2020-01-23. Estimated completion is 2023-03-30.
What conditions does trial NCT04247126 study?
This clinical trial studies the following conditions: Breast Cancer, Pancreatic Cancer, Advanced Solid Tumor, Small-cell Lung Cancer.
What interventions are being tested in trial NCT04247126?
The interventions under investigation include: Fulvestrant (DRUG), Gemcitabine (DRUG), Nab-paclitaxel (DRUG), SY-5609 (DRUG).
Who is sponsoring clinical trial NCT04247126?
This trial is sponsored by Syros Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04247126 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Georgia, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04247126's enrollment target sits among peer trials
105 550th of 1224 higher than 673 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
VS-6766+Abema+Fulv in Met HR+/HER- BC
RECRUITING · Phase 1
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
RECRUITING · Phase 1
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI